Hikma Pharmaceuticals Regulatory News (HIK)

3 Apr 2007 13:14

Hikma Pharmaceuticals Plc03 April 2007 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 3 April 2007: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) announcesthat the Remuneration Committee has made the following awards under the HikmaPharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP") to PersonsDischarging Managerial Responsibility ("PDMRs") of the Company. Awards were made on 2 April 2007 at a price of £3.87 per ordinary share asfollows:- Name of PDMR Number of LTIP Shares Bassam Kanaan 30,000Nabil Rizk 30,000Taghreed Al-Shunnar 25,000Majda Labadi 25,000Gabriel Kalisse 25,000Mike Raya 25,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2006, the Grouphad revenue of $317 million and profit attributable to shareholders of $54.5million. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange